Centre of Excellence in Severe AsthmaCentre of Excellence in Severe Asthma
severeasthma@newcastle.edu.au
Twitter
  • Home
  • About Us
  • Our People
  • Research
    • Overview
    • Expanded Research Themes
    • List of Funded Projects
    • Publication List
    • Consumer Reference Group
    • The MASTER Study
  • News & Events
    • News
    • Upcoming Events
    • Past Events
    • Funding Opportunities
  • Tools & Resources
    • Overview
    • Clinical Resources
    • Past Webinars
    • Highlighted Publications
    • Newsletters & Annual Reports
    • Journal Club
    • Useful Links
    • For People with Severe Asthma & Their Families
    • For Healthcare Professionals
  • Contact Us
  • Severe Asthma Toolkit

Biomarkers of Inhaled Corticosteroid for COPD

Home Biomarkers of Inhaled Corticosteroid for COPD

“Biomarkers of Inhaled Corticosteroid Respond in COPD” presented by Prof. Ian Pavord

As part of our ongoing seminar series, the Centre of Excellence in Severe Asthma hosted Prof. Ian Pavord for a webinar on “Biomarkers of Inhaled Corticosteroid Respond in COPD” on 20 June 2016.

Presentation Summary:

Corticosteroid treatment is effective at reducing exacerbation rates in people with COPD. The benefit of treatment is balanced by an increased risk of pneumonias and steroid-associated side effects. Biomarkers have been proposed to identify the patients most likely to respond to steroid treatment.

Biomarkers can provide information about the mechanisms underlying disease in individual patients. Eosinophil numbers are increased in a subset of COPD patients. Increased sputum eosinophil numbers are associated with a better response to steroid treatment.

Blood eosinophil counts are more readily accessible than sputum assessment. Blood eosinophil counts are a useful biomarker of COPD exacerbations. Increased blood eosinophil counts also predict response steroid treatment.

A “treatable traits” approach to treating airways disease is proposed. Treatment should be targeted to the disease mechanisms identified in each patient.

Key Points:

  • Corticosteroids are primarily used as a risk-reduction strategy in COPD treatment
  • Inhaled corticosteroid (ICS) treatment reduces COPD exacerbations, with no effect on decline in lung function (Burge et al BMJ 2000)
  • Corticosteroid treatment also increases rates of pneumonia (Calverley et al. NEJM 2007)
  • GOLD Guidelines (2011) recommend use of corticosteroids for risk-reduction, in COPD patients with previous exacerbation history or airflow limitation
  • There is increasing concern about the costs of treatments and assessing cost/benefit for healthcare expenditures
  • Triple therapy for COPD is of questionable cost/benefit value
  • There is increasing recognition of adverse effects of long-term corticosteroid use
  • New insights into the mechanisms regulating COPD pathogenesis may provide a more targeted approach for treatment
  • Sputum eosinophil counts are increased in a subset of COPD patients
  • Higher sputum eosinophil numbers are associated with a better response to steroid therapy
  • Treatment where steroid dose is guided by sputum eosinophil number reduces exacerbations for COPD patients
  • Availability of sputum inflammation assessment is limited in most clinical settings
  • Blood eosinophil count is a useful biomarker of eosinophilic exacerbations
  • ICS treatment reduces exacerbation rates in COPD patients with higher blood eosinophil counts (Pascoe Lancet Resp Med 2015)
  • Withdrawal of ICS treatment is associated with increased exacerbation risk only in patients with elevated blood eosinophil counts (Watz Lancet Resp Med 2016)
  • Pneumonia risk following ICS treatment is independent of blood eosinophil counts
  • Additional biomarkers of Type-2 inflammation include fractional exhaled nitric oxide (FeNO) and periostin
  • In COPD, FeNO level does not correlate well with sputum eosinophil numbers and smoking has variable effects on FeNO level
  • There is no correlation between periostin and sputum eosinophil counts in COPD
  • A “treatable traits” management approach should be applied for airways disease based on the type of airways inflammation rather than disease label (e.g. COPD)
  • Symptoms caused by airflow limitation should be treated using bronchodilators
  • Exacerbation risk associated with eosinophilic inflammation should be treated using ICS
  • This approach could support a more efficient use of existing treatment strategies

About Prof. Ian Pavord:Ian Pavord Inhaled Corticosteroids

Prof. Ian Pavord is Professor of Respiratory Medicine at the University of Oxford and Honorary Consultant Physician at the Oxford University Hospitals.

He has published 260 scientific papers, including three of the 20 most cited papers in the field in the last 10 years. He has an H-index of 65. His main contribution has been to develop new methods to assess and treat airway inflammation and airway diseases.

He has been joint Chief Medical Advisor to Asthma UK since May 2008 and joint Editor of Thorax since 2010.

Prof. Pavord’s travel was supported by Menarini.

To view other webinars on Severe Asthma please click here

News

Clinical Recommendations for COVID-19 in Severe Asthma
Clinical Recommendations for COVID-19 in Severe Asthma

May 15th, 2020

Read More
CANCELLED: CRE Severe Asthma Webinar: "Exercise-induced Laryngeal Obstruction (EILO). What is it, who gets it, how you assess it, what you do about it?"
CANCELLED: CRE Severe Asthma Webinar: "Exercise-induced Laryngeal Obstruction (EILO). What is it, who gets it, how you assess it, what you do about it?"

March 13th, 2020

Read More
POSTPONED: Laryngeal Dysfunction Workshop
POSTPONED: Laryngeal Dysfunction Workshop

March 13th, 2020

Read More

Join Our Mailing List

Funded By

Twitter Feed

Tweets by SevereAsthmaCRE

Contact us

Postal Address
NHMRC Centre of Excellence in Severe Asthma
c/o Hunter Medical Research Institute
Locked Bag 1000
New Lambton, NSW 2305
AUSTRALIA
Email
Twitter
  • Website Terms of Use
Copyright 2016    CRICOS Provider Number 00109J    The University of Newcastle, Australia